We have located links that may give you full text access.
Spectrum of pulmonary aspergillosis in Hyper IgE syndrome with autosomal dominant STAT3 deficiency.
Journal of Allergy and Clinical Immunology in Practice 2019 March 14
BACKGROUND: Autosomal dominant signal transducer and activator of transcription 3 (STAT3) deficiency predisposes to recurrent bacterial pneumonia, complicated by bronchiectasis and cavitations. Aspergillosis is a major cause of morbidity in these patients. However, its diagnosis, classification, and treatment are challenging.
OBJECTIVE: We aimed to assess the prevalence and describe the clinical, mycological, and radiological presentation and related therapy and outcome of Aspergillus infections of the respiratory tract in the STAT3 deficient patients of the National French cohort.
METHODS: We performed a retrospective study of all pulmonary aspergillosis cases in STAT3 deficient patients (n=74). Clinical and mycological data were collected up to October 2015 and imaging was centralized.
MAIN RESULTS: Twenty-one episodes of pulmonary aspergillosis in 13 (17.5%) STAT3deficient patients were identified. The median age at first episode was 13 years (IQR 10-26). Ninety percent of patients had previous bronchiectasis or cavitations. Infections were classified as follows: five single aspergilloma, nine chronic cavity pulmonary aspergillosis (CCPA), five allergic broncho-pulmonary aspergillosis-like disease (ABPA-like), and two mixed forms of concomitant ABPA-like and CCPA. No invasive aspergillosis cases were identified. Aspergillus sp. were isolated in 71% of episodes and anti-Aspergillus antibodies in 93%. Eleven episodes were breakthrough infections. Antifungal treatment was prolonged with a median of 13 months and six patients (seven episodes) required surgery with a high rate of post-surgical complications. One patient died and six relapsed.
CONCLUSION: Chronic and allergic forms of aspergillosis occurred in 17.5% of STAT3 deficient patients, mostly in lung cavities. Almost half had recurrences, despite prolonged antifungal treatment and/or surgery.
OBJECTIVE: We aimed to assess the prevalence and describe the clinical, mycological, and radiological presentation and related therapy and outcome of Aspergillus infections of the respiratory tract in the STAT3 deficient patients of the National French cohort.
METHODS: We performed a retrospective study of all pulmonary aspergillosis cases in STAT3 deficient patients (n=74). Clinical and mycological data were collected up to October 2015 and imaging was centralized.
MAIN RESULTS: Twenty-one episodes of pulmonary aspergillosis in 13 (17.5%) STAT3deficient patients were identified. The median age at first episode was 13 years (IQR 10-26). Ninety percent of patients had previous bronchiectasis or cavitations. Infections were classified as follows: five single aspergilloma, nine chronic cavity pulmonary aspergillosis (CCPA), five allergic broncho-pulmonary aspergillosis-like disease (ABPA-like), and two mixed forms of concomitant ABPA-like and CCPA. No invasive aspergillosis cases were identified. Aspergillus sp. were isolated in 71% of episodes and anti-Aspergillus antibodies in 93%. Eleven episodes were breakthrough infections. Antifungal treatment was prolonged with a median of 13 months and six patients (seven episodes) required surgery with a high rate of post-surgical complications. One patient died and six relapsed.
CONCLUSION: Chronic and allergic forms of aspergillosis occurred in 17.5% of STAT3 deficient patients, mostly in lung cavities. Almost half had recurrences, despite prolonged antifungal treatment and/or surgery.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app